Literature DB >> 33170923

Speed, Evidence, and Safety Characteristics of Vaccine Approvals by the US Food and Drug Administration.

Jeremy Puthumana1, Alexander C Egilman2, Audrey D Zhang3, Jason L Schwartz4, Joseph S Ross1,2,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33170923      PMCID： PMC7656319          DOI： 10.1001/jamainternmed.2020.7472

Source DB:  PubMed          Journal:  JAMA Intern Med        ISSN： 2168-6106            Impact factor:   21.873


× No keyword cloud information.
  4 in total

Review 1.  Challenges and Issues of Anti-SARS-CoV-2 Vaccines.

Authors:  Sophie Blumental; Patrice Debré
Journal:  Front Med (Lausanne)       Date:  2021-05-14

2.  Premarket Development Times for Innovative Vaccines--To What Extent Are the Coronavirus Disease 2019 (COVID-19) Vaccines Outliers?

Authors:  Reed F Beall; Aaron S Kesselheim; Aidan Hollis
Journal:  Clin Infect Dis       Date:  2022-01-29       Impact factor: 9.079

3.  Anaphylaxis rates associated with COVID-19 vaccines are comparable to those of other vaccines.

Authors:  Helena C Maltezou; Cleo Anastassopoulou; Sophia Hatziantoniou; Gregory A Poland; Athanasios Tsakris
Journal:  Vaccine       Date:  2021-11-27       Impact factor: 3.641

4.  A study of the evolution of the third COVID-19 pandemic wave in the Athens metropolitan area, Greece, through two cross-sectional seroepidemiological surveys: March, June 2021.

Authors:  Helena C Maltezou; Bettina Krumbholz; Maria Mavrouli; Maria Tseroni; Maria N Gamaletsou; Evanthia Botsa; Cleo Anastassopoulou; Aristofanis Gikas; Evanthia Fournarakou; Maria Kavieri; Aikaterini Koureli; Dionysia Mandilara; Aikaterini Marinopoulou; Argyro Theodorikakou; Panagiotis Tsiahris; Anastasia Zarzali; Spyridon Pournaras; Athanasia Lourida; Ioannis Elefsiniotis; Georgia Vrioni; Nikolaos V Sipsas; Athanasios Tsakris
Journal:  J Med Virol       Date:  2021-12-04       Impact factor: 2.327
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.